Pfizer Ireland

Milestones as listed on pfizer.ie, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on pfizer.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on pfizer.ie, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on pfizer.ie, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Pfizer (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.

Clinical trials 225 in our ClinicalTrials.gov registers · 18 in the EU register

Showing 10 of 225, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 112 compounds

EU trials register (CTIS) 18 authorised or ongoing · 1 in Ireland

• C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer2025-524825-42-00 · Phase II · Authorised · site in Ireland
• A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 are Tolerated and Act in the Body in Healthy Adults or Adults With Mild-to-Moderate Asthma2026-526260-21-00 · Phase I · Authorised
• C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer2025-524686-24-00 · Phase II · Ongoing
• C4931004 - A Phase 3, Randomized Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Catch-Up Vaccination Regimen of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Children and Adolescents2025-523445-10-00 · Phase III · Authorised
• C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis2025-523100-77-00 · Phase II · Ongoing
• A Study to Learn About the Study Medicine Called PF-08032562 in People with Advanced or Metastatic Solid Tumors2025-524387-38-00 · Phase I · Authorised
• C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER2025-523521-18-00 · Phase III · Ongoing
• C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY2025-523660-21-00 · Phase III · Ongoing

Recent approvals

• Butorphanol Tartrate Preservative FreeFDA · Butorphanol Tartrate · 23 Jan 1997 · Generic (ANDA)
• Cleocin HydrochlorideFDA · Clindamycin Hydrochloride · 22 Feb 1970 · New Drug (NDA)

Medicine shortages 54 in the FDA list · 15 German notices

• Dexmedetomidine Hydrochloride InjectionUS (FDA) · in shortage · updated 2 Oct 2026
• Methylprednisolone Acetate InjectionUS (FDA) · in shortage · updated 2 Oct 2026
• Carboplatin InjectionUS (FDA) · in shortage · updated 1 Oct 2026
• Sodium Bicarbonate InjectionUS (FDA) · in shortage · updated 1 Oct 2026
• Midazolam Hydrochloride InjectionUS (FDA) · in shortage · updated 1 Oct 2026
• Methotrexate Sodium InjectionUS (FDA) · in shortage · updated 1 Oct 2026
• Hydromorphone Hydrochloride InjectionUS (FDA) · in shortage · updated 1 Oct 2026
• Sodium Acetate InjectionUS (FDA) · in shortage · updated 1 Oct 2026
• Minprostin E2 Vaginalgel 2mgGermany (BfArM) · 1 Dec 2025 to 30 Nov 2026
• Lantarel 7,5 mgGermany (BfArM) · 1 Sep 2026 to 31 Dec 2026
• Lantarel 7,5 mgGermany (BfArM) · 1 Sep 2026 to 31 Dec 2026
• AmsparityGermany (BfArM) · 1 Nov 2025 to 31 Dec 2026
• AtgamGermany (BfArM) · 15 Sep 2026 to 30 Nov 2026

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 67 of its medicines · 56 current

• Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancerNICE TA1130 · Optimised · 11 Feb 2026
• Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorNICE TA1103 · Recommended · 21 Oct 2025
• Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesNICE TA1073 · Optimised · 24 Jun 2025
• Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsNICE TA1023 · Optimised (Cancer Drugs Fund) · 11 Dec 2024
• Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerNICE TA1021 · Optimised · 4 Dec 2024
• Tafamidis for treating transthyretin amyloidosis with cardiomyopathyNICE TA984 · Recommended · 19 Jun 2024
• Voxelotor for treating haemolytic anaemia caused by sickle cell diseaseNICE TA981 · Optimised · 12 Jun 2024
• Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)NICE TA972 · Terminated (no company submission) · 22 May 2024

Appraisals of medicines whose first EU or US authorisation was held by this company, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Pfizer): founded 1849, headquarters New York City, website pfizer.com. Wikidata Q206921 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Pfizer; Pfizer Inc.; Pfizer Europe MA EEIG; Pfizer Healthcare Ireland Unlimited Company; Pfizer Service Company BVBA; Pfizer Ireland Pharmaceuticals and 7 more. Spot a wrong match? Tell us.

Group figures for Pfizer Inc., the parent company. From the annual reports Pfizer Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 14 active in the CRO register · 5 dissolved not shown

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Pfizer Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.